These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11703354)

  • 1. Thalidomide is effective for extramedullary relapse of multiple myeloma post-allogeneic bone marrow transplantation.
    Biagi JJ; Prince HM
    Br J Haematol; 2001 Nov; 115(2):484-5. PubMed ID: 11703354
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
    Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM
    Bone Marrow Transplant; 2001 Dec; 28(12):1145-50. PubMed ID: 11803357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
    Leotta S; Pirosa MC; Markovic U; Scalise L; Bulla A; Sapienza G; Di Giorgio MA; Martino EA; Curto Pelle A; Leotta V; Milone G; Cupri A; Vaddinelli D; Villari L; Conticello C; Milone G
    Chemotherapy; 2019; 64(2):110-114. PubMed ID: 31533095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extramedullary multiple myeloma escapes the effect of thalidomide.
    Rosiñol L; Cibeira MT; Bladé J; Esteve J; Aymerich M; Rozman M; Segarra M; Cid MC; Filella X; Montserrat E
    Haematologica; 2004 Jul; 89(7):832-6. PubMed ID: 15257935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide in multiple myeloma.
    Rajkumar SV
    Oncology (Williston Park); 2000 Dec; 14(12 Suppl 13):11-6. PubMed ID: 11204667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of thalidomide in refractory multiple myeloma.
    Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
    N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide--a revival story.
    Raje N; Anderson K
    N Engl J Med; 1999 Nov; 341(21):1606-9. PubMed ID: 10564693
    [No Abstract]   [Full Text] [Related]  

  • 9. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
    Hattori Y; Kakimoto T
    Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105
    [No Abstract]   [Full Text] [Related]  

  • 10. The future role of thalidomide in multiple myeloma.
    Boccadoro M; Blade J; Attal M; Palumbo A
    Acta Haematol; 2005; 114 Suppl 1():18-22. PubMed ID: 16166768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients.
    Corso A; Lorenzi A; Zappasodi P; Invernizzi R; Vanelli L; Lazzarino M
    Haematologica; 2003 Aug; 88(8):958-60. PubMed ID: 12935985
    [No Abstract]   [Full Text] [Related]  

  • 12. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide in refractory and relapsing multiple myeloma.
    Bladé J; Esteve J; Rosiñol L; Perales M; Montoto S; Tuset M; Montserrat E
    Semin Oncol; 2001 Dec; 28(6):588-92. PubMed ID: 11740814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
    Rajkumar SV; Witzig TE
    Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
    Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB
    Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New trends in the therapy of myeloma].
    Jantunen E; Nousiainen T
    Duodecim; 2000; 116(9):937-9. PubMed ID: 11988994
    [No Abstract]   [Full Text] [Related]  

  • 17. Allogeneic transplantation in multiple myeloma: a potential renaissance in the era of novel therapies?
    Richardson P
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1078-9. PubMed ID: 24956499
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
    Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
    Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
    [No Abstract]   [Full Text] [Related]  

  • 19. Thalidomide: present and future in multiple myeloma.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma.
    Ribatti D; Vacca A
    Ann Hematol; 2003 Apr; 82(4):262. PubMed ID: 12707735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.